Sentences with phrase «litigation under the securities laws»

In his securities practice he has represented issuers and underwriters in public offerings and private placements; prepared and reviewed proxy statements and other periodic filings under the Exchange Act; represented clients in proxy contests; represented non-interested directors of an investment company; and handled civil litigation under the securities laws.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Laura focuses her practice on civil litigation and regulatory investigations under the federal securities laws as well as state law claims arising from corporate transactions, such as suits seeking to enjoin mergers and acquisitions and appraisals.

Securities work comes more under the capital markets umbrella.The team still does «securities litigation, M&A shareholder actions and derivative law suiSecurities work comes more under the capital markets umbrella.The team still does «securities litigation, M&A shareholder actions and derivative law suisecurities litigation, M&A shareholder actions and derivative law suits.»

Jack has over twenty years of experience in numerous types of commercial litigation matters, with substantial representations of clients in many matters involving environmental litigation, including five trials pursuant to the Comprehensive Environmental Response, Compensation and Liability Act, significant architectural, engineering and construction disputes, business acquisition and transactional disputes, including takeover / merger and acquisition litigation, claims under purchase and sales and indemnity contracts, securities law litigation, insurance coverage on behalf of the insured, and legal issues relating to medical records release and copying.

David has acted for clients in a wide range of disputes, including shareholder and partnership disputes, securities litigation, class action defence, proceedings under the Competition Act, employment law disputes, contract disputes, breach of confidence / intellectual property disputes, fidelity bond claims, and professional negligence claims.

The series covers a broad range of securities, corporate governance, and executive, equity, and director compensation issues, as well as relevant litigation developments and the ever - changing responsibilities of board members under US state law.

In 2016, she was recognized as a «Rising Star» for Litigation by Euromoney in its 2016 Americas Women in Business Law Awards, and in 2017 she was named to Benchmark Litigation's «Under 40 Hotlist» and recognized as a recommended lawyer for Securities Litigation by Legal 500.

Jim has defended banks in connection with suits arising under various truth in lending laws as well the Uniform Commercial Code, has prosecuted multi district litigation involving injuries purportedly caused by the ingestion of certain prescription and over-the-counter drugs and has engaged in sales practices and securities litigation arising under common law, a myriad of consumer protection statutes, and the Securities and Exchsecurities litigation arising under common law, a myriad of consumer protection statutes, and the Securities and ExchSecurities and Exchange Acts.

Kristine Maher represents corporate clients in a variety of commercial litigation matters, including Employee Retirement Income Security Act (ERISA) litigation and class action cases involving claims under various state consumer protection laws and federal laws such as the civil Racketeer Influenced and Corrupt Organizations (RICO) Act.

Closed - door, or executive, sessions are only permitted under the open meetings law for a few reasons such as if the topic involves a personnel issue, a course of action for security personnel or litigation.

Experienced attorney, Harvard Law School, J.D. 1991 (cum laude), AV rated, Expertise in all aspects of investigation, discovery, depositions, and trial of complex commercial litigation matters, multi-district litigation, ownership of intellectual property, international child abduction under the Hague Convention, insurance coverage, legal malpractice, securities fraud, commercial real estate, tax disputes, employee disputes...